US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Skye Bioscience Inc.

0.6490

-0.0062-0.95%

Post-market: 0.6337-0.0153-2.36%19:58 EDT

Volume:279.30K

Turnover:180.81K

Market Cap:21.66M

PE:-0.46

High:0.6600

Open:0.6600

Low:0.6337

Close:0.6552

52wk High:5.75

52wk Low:0.6100

Shares:33.38M

Float Shares:19.88M

Volume Ratio:1.05

T/O Rate:1.40%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.4100

EPS(LYR):-1.4100

ROE:-126.85%

ROA:-71.93%

PB:1.08

PE(LYR):-0.46

Loading ...

Overview Company News Filings

Skye Bioscience receives Nasdaq notice for SKYE bid price below $1 for 30 days

Skye Bioscience (SKYE) Receives a Hold from Cantor Fitzgerald

Analysts Offer Insights on Healthcare Companies: Skye Bioscience (SKYE) and Sandoz Group Ltd (OtherSDZXF)

Skye Bioscience Inc reports results for the quarter ended December 31 - Earnings Summary

Skye Bioscience Q4 EPS $(0.36) Misses $(0.30) Estimate

Skye Bioscience FY 2025 net loss rises 111% to USD 55.92 million

Press Release: Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Skye Bioscience Inc expected to post a loss of 30 cents a share - Earnings Preview

Skye Bioscience Publishes Corporate Presentation on Nimacimab-Semaglutide Obesity Combination Strategy

Skye Bioscience Inc. to Announce 2025 Financial Results and Business Update on Conference Call

Skye Bioscience Publishes Corporate Presentation on Nimacimab–Semaglutide Obesity Combination Strategy

BRIEF-Skye Bioscience Says Kaitlyn Arsenault To Step Down As CFO Effective Feb 20

Skye Bioscience Inc - Kaitlyn Arsenault to Step Down as CFO Effective Feb 20, 2026 - SEC Filing

THOMSON REUTERS

Skye Bioscience CFO Kaitlyn Arsenault to Step Down as CEO Punit Dhillon Becomes Principal Accounting Officer

Halozyme 2025 revenue up 38%, Q4 EPS misses estimates

BRIEF-Skye Reports Positive Cbeyond Phase 2A Extension Interim Study Results For Nimacimab

Skye Bioscience Reports 22% Weight Loss at 52 Weeks With Nimacimab and Semaglutide Combination in Phase 2a Study

Skye Bioscience Inc - 22.3% Weight Loss at 52 Weeks With Nimacimab + Semaglutide (2.4 Mg) Combination

THOMSON REUTERS

Skye Bioscience Inc - Full Topline Reporting of Cbeyond Phase 2a Data Expected Q3 2026

THOMSON REUTERS

Skye Reports Positive Cbeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/SKYE/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"SKYE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SKYE\",,,,,undefined,":{"symbol":"SKYE","market":"US","secType":"STK","nameCN":"Skye Bioscience Inc.","latestPrice":0.649,"timestamp":1774036800000,"preClose":0.6552,"halted":0,"volume":279299,"hourTrading":{"tag":"盘后","latestPrice":0.6337,"preClose":0.649,"latestTime":"19:58 EDT","volume":16830,"amount":10826.913,"timestamp":1774051099352,"change":-0.0153,"changeRate":-0.023575,"amplitude":0.023729},"delay":0,"changeRate":-0.009462759462759438,"floatShares":19882200,"shares":33378764,"eps":-1.410011,"marketStatus":"Market Closed","change":-0.0062,"latestTime":"03-20 16:00:00 EDT","open":0.66,"high":0.66,"low":0.6337,"amount":180809.80480195998,"amplitude":0.04014,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.410011,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"symbolChange":{"newSymbol":"SKYED","executeDate":"2023-09-08"},"adr":0,"exchange":"NASDAQ","adjPreClose":0.6552,"preHourTrading":{"tag":"盘前","latestPrice":0.6551,"preClose":0.6552,"latestTime":"09:20 EDT","volume":1522,"amount":990.9031226,"timestamp":1774012849995,"change":-0.0001,"changeRate":-0.000153,"amplitude":0.023199},"postHourTrading":{"tag":"盘后","latestPrice":0.6337,"preClose":0.649,"latestTime":"19:58 EDT","volume":16830,"amount":10826.913,"timestamp":1774051099352,"change":-0.0153,"changeRate":-0.023575,"amplitude":0.023729},"volumeRatio":1.052089,"impliedVol":1.1162,"impliedVolPercentile":0.3904},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SKYE\",,,,,undefined,":{"symbol":"SKYE","floatShares":19882200,"roa":"-71.93%","roe":"-126.85%","lyrEps":-1.410011,"volumeRatio":1.052089,"shares":33378764,"dividePrice":0,"high":0.66,"amplitude":0.04014,"preClose":0.6552,"low":0.6337,"week52Low":0.61,"pbRate":"1.08","week52High":5.75,"institutionHeld":0,"latestPrice":0.649,"eps":-1.410011,"divideRate":0,"volume":279299,"delay":0,"ttmEps":-1.410011,"open":0.66,"prevYearClose":0.7497,"prevWeekClose":0.6603,"prevMonthClose":0.7449,"prevQuarterClose":0.7497,"fiveDayClose":0.6603,"twentyDayClose":0.7815,"sixtyDayClose":0.92},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SKYE\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-10","symbol":"SKYE","fiscalQuarterEnding":"2025/12","expectedEps":-0.29,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1773115200000,"reportTimeType":"post","actualEps":-0.36},{"market":"US","date":"2025-11-10","symbol":"SKYE","fiscalQuarterEnding":"2025/09","expectedEps":-0.33,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"post","actualEps":-0.32},{"market":"US","date":"2025-08-07","symbol":"SKYE","fiscalQuarterEnding":"2025/06","expectedEps":-0.34,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"post","actualEps":-0.44},{"market":"US","date":"2025-05-08","symbol":"SKYE","fiscalQuarterEnding":"2025/03","expectedEps":-0.31,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.28},{"market":"US","date":"2025-03-20","symbol":"SKYE","fiscalQuarterEnding":"2024/12","expectedEps":-0.3,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1742443200000,"reportTimeType":"post","actualEps":-0.24}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SKYE\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SKYE\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.625,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.625,"analysts":8,"updateTime":1759809600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SKYE\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SKYE","date":"2026-03-19","current":-0.46028,"percent":0.995726,"low":-12.94129,"twenty":-4.568894,"median":-3.077727,"eighty":-1.060422,"high":-0.3941,"avg":-3.471331,"sd":2.574853,"marketCap":22470583},"quantilePoints":[{"date":"2024-04-12","current":-9.459964,"twenty":-9.513638,"median":-9.459964,"eighty":-7.885539,"marketCap":356118289},{"date":"2024-04-19","current":-12.650558,"twenty":-12.435864,"median":-9.657512,"eighty":-9.495746,"marketCap":476227531},{"date":"2024-04-26","current":-9.579238,"twenty":-12.081022,"median":-9.691058,"eighty":-9.561347,"marketCap":360608354},{"date":"2024-05-03","current":-9.683603,"twenty":-11.635233,"median":-9.68733,"eighty":-9.561347,"marketCap":364537161},{"date":"2024-05-10","current":-8.997775,"twenty":-10.807766,"median":-9.638876,"eighty":-9.507673,"marketCap":338719287},{"date":"2024-05-17","current":-9.168,"twenty":-10.15772,"median":-9.601602,"eighty":-9.22813,"marketCap":343770610},{"date":"2024-05-24","current":-8.952556,"twenty":-9.700003,"median":-9.54942,"eighty":-8.9931,"marketCap":335692167},{"date":"2024-05-31","current":-8.720508,"twenty":-9.691058,"median":-9.489815,"eighty":-8.983995,"marketCap":326991116},{"date":"2024-06-07","current":-8.47349,"twenty":-9.691058,"median":-9.389145,"eighty":-8.952556,"marketCap":317728707},{"date":"2024-06-14","current":-8.069277,"twenty":-9.691058,"median":-9.18753,"eighty":-8.690567,"marketCap":302572037},{"date":"2024-06-21","current":-6.684476,"twenty":-9.685094,"median":-9.060284,"eighty":-8.473188,"marketCap":250646409},{"date":"2024-06-28","current":-5.434411,"twenty":-9.674658,"median":-9.022864,"eighty":-8.245631,"marketCap":203773004},{"date":"2024-07-05","current":-5.58412,"twenty":-9.638876,"median":-8.993879,"eighty":-7.844715,"marketCap":209386586},{"date":"2024-07-12","current":-4.873005,"twenty":-9.631421,"median":-8.980898,"eighty":-7.11863,"marketCap":182722074},{"date":"2024-07-15","current":-4.820607,"twenty":-9.62993,"median":-8.974213,"eighty":-6.892464,"marketCap":180757321},{"date":"2024-08-02","current":-4.102007,"twenty":-9.628439,"median":-8.967527,"eighty":-6.745055,"marketCap":153812130},{"date":"2024-08-09","current":-3.735222,"twenty":-9.606075,"median":-8.870216,"eighty":-5.58412,"marketCap":140058855},{"date":"2024-08-16","current":-3.615791,"twenty":-9.579238,"median":-8.690567,"eighty":-4.690361,"marketCap":152904981},{"date":"2024-08-23","current":-3.787972,"twenty":-9.567311,"median":-8.506414,"eighty":-4.17237,"marketCap":160186171},{"date":"2024-08-30","current":-4.584307,"twenty":-9.543456,"median":-8.189044,"eighty":-4.185844,"marketCap":193861673},{"date":"2024-09-06","current":-4.347559,"twenty":-9.525571,"median":-8.069277,"eighty":-4.204574,"marketCap":183850037},{"date":"2024-09-13","current":-4.304513,"twenty":-9.489808,"median":-7.545298,"eighty":-4.204574,"marketCap":182029740},{"date":"2024-09-20","current":-3.93863,"twenty":-9.483818,"median":-7.11863,"eighty":-4.170873,"marketCap":166557212},{"date":"2024-09-27","current":-2.840979,"twenty":-9.431636,"median":-6.35886,"eighty":-4.072065,"marketCap":120139628},{"date":"2024-10-04","current":-2.56836,"twenty":-9.296072,"median":-5.58412,"eighty":-3.802872,"marketCap":108611078},{"date":"2024-10-11","current":-2.683147,"twenty":-9.199248,"median":-5.224584,"eighty":-3.740033,"marketCap":113465204},{"date":"2024-10-18","current":-3.034682,"twenty":-9.153032,"median":-4.873005,"eighty":-3.308736,"marketCap":128330966},{"date":"2024-10-25","current":-3.501004,"twenty":-9.080009,"median":-4.593919,"eighty":-3.325954,"marketCap":148050855},{"date":"2024-10-31","current":-3.651662,"twenty":-9.02741,"median":-4.557114,"eighty":-3.343172,"marketCap":154421896},{"date":"2024-11-08","current":-7.770049,"twenty":-9.018318,"median":-4.55561,"eighty":-3.379043,"marketCap":165040297},{"date":"2024-11-15","current":-7.870031,"twenty":-8.997775,"median":-4.571462,"eighty":-3.501004,"marketCap":167163977},{"date":"2024-11-22","current":-5.956085,"twenty":-8.989983,"median":-4.820607,"eighty":-3.501004,"marketCap":126510669},{"date":"2024-11-29","current":-6.413147,"twenty":-8.983995,"median":-4.921494,"eighty":-3.53544,"marketCap":136218922},{"date":"2024-12-06","current":-5.070528,"twenty":-8.981218,"median":-5.25247,"eighty":-3.595703,"marketCap":107700929},{"date":"2024-12-13","current":-4.784865,"twenty":-8.970201,"median":-5.21336,"eighty":-3.614356,"marketCap":101633271},{"date":"2024-12-20","current":-4.084989,"twenty":-8.95555,"median":-5.042643,"eighty":-3.644488,"marketCap":86767509},{"date":"2024-12-27","current":-3.799325,"twenty":-8.952556,"median":-4.89725,"eighty":-3.64221,"marketCap":80699851},{"date":"2025-01-03","current":-4.070706,"twenty":-8.886684,"median":-4.82416,"eighty":-3.64221,"marketCap":86464126},{"date":"2025-01-10","current":-4.427785,"twenty":-8.774403,"median":-4.734873,"eighty":-3.64221,"marketCap":94048699},{"date":"2025-01-17","current":-3.856458,"twenty":-8.71452,"median":-4.60353,"eighty":-3.6441,"marketCap":81913383},{"date":"2025-01-24","current":-3.727909,"twenty":-8.690567,"median":-4.558618,"eighty":-3.651662,"marketCap":79182936},{"date":"2025-01-31","current":-5.356192,"twenty":-8.660625,"median":-4.557114,"eighty":-3.694707,"marketCap":113768587},{"date":"2025-02-07","current":-4.256387,"twenty":-8.539337,"median":-4.55561,"eighty":-3.699343,"marketCap":90408104},{"date":"2025-02-14","current":-4.370652,"twenty":-8.47349,"median":-4.466458,"eighty":-3.699343,"marketCap":92835167},{"date":"2025-02-21","current":-4.470635,"twenty":-8.472282,"median":-4.477777,"eighty":-3.722196,"marketCap":94958847},{"date":"2025-02-28","current":-3.827892,"twenty":-8.245631,"median":-4.442068,"eighty":-3.730044,"marketCap":81306617},{"date":"2025-03-07","current":-3.670777,"twenty":-8.162365,"median":-4.40636,"eighty":-3.699343,"marketCap":77969405},{"date":"2025-03-14","current":-3.463671,"twenty":-8.134468,"median":-4.354733,"eighty":-3.698416,"marketCap":73570353},{"date":"2025-03-21","current":-2.203547,"twenty":-8.081254,"median":-4.304513,"eighty":-3.649772,"marketCap":58541914},{"date":"2025-03-28","current":-2.471704,"twenty":-7.90988,"median":-4.297339,"eighty":-3.6255,"marketCap":65666062},{"date":"2025-04-04","current":-1.632257,"twenty":-7.858605,"median":-4.256387,"eighty":-3.582221,"marketCap":43364381},{"date":"2025-04-11","current":-1.562303,"twenty":-7.846922,"median":-4.225597,"eighty":-3.501004,"marketCap":41505907},{"date":"2025-04-17","current":-1.842119,"twenty":-7.799915,"median":-4.189726,"eighty":-3.364695,"marketCap":48939801},{"date":"2025-04-25","current":-2.086958,"twenty":-7.727199,"median":-4.165203,"eighty":-3.259602,"marketCap":55444458},{"date":"2025-05-02","current":-2.366773,"twenty":-7.630073,"median":-4.156405,"eighty":-3.056205,"marketCap":62878352},{"date":"2025-05-09","current":-1.698098,"twenty":-7.560926,"median":-4.127838,"eighty":-2.911286,"marketCap":55444458},{"date":"2025-05-16","current":-1.907406,"twenty":-7.545298,"median":-4.116978,"eighty":-2.799369,"marketCap":62278559},{"date":"2025-05-23","current":-1.964344,"twenty":-7.500386,"median":-4.077848,"eighty":-2.746856,"marketCap":64137621},{"date":"2025-05-30","current":-2.011792,"twenty":-7.329718,"median":-4.070706,"eighty":-2.683147,"marketCap":65686838},{"date":"2025-06-06","current":-2.040261,"twenty":-7.099247,"median":-4.06458,"eighty":-2.616276,"marketCap":66616369},{"date":"2025-06-13","current":-2.05924,"twenty":-6.976473,"median":-4.013573,"eighty":-2.54373,"marketCap":67236056},{"date":"2025-06-20","current":-2.030771,"twenty":-6.805634,"median":-3.979786,"eighty":-2.387759,"marketCap":66306526},{"date":"2025-06-27","current":-4.033073,"twenty":-6.650207,"median":-3.970723,"eighty":-2.387759,"marketCap":131683521},{"date":"2025-07-03","current":-4.374698,"twenty":-6.513129,"median":-3.970723,"eighty":-2.471704,"marketCap":142837890},{"date":"2025-07-11","current":-3.738896,"twenty":-6.413147,"median":-3.970723,"eighty":-2.503792,"marketCap":122078370},{"date":"2025-07-18","current":-3.530125,"twenty":-6.413147,"median":-3.966646,"eighty":-2.541658,"marketCap":115261811},{"date":"2025-07-25","current":-3.805323,"twenty":-6.298881,"median":-3.947535,"eighty":-2.546837,"marketCap":124247275},{"date":"2025-08-01","current":-3.387782,"twenty":-6.198899,"median":-3.902759,"eighty":-2.561185,"marketCap":110614158},{"date":"2025-08-08","current":-3.368802,"twenty":-6.1132,"median":-3.885025,"eighty":-2.56836,"marketCap":109994470},{"date":"2025-08-15","current":-2.391434,"twenty":-6.1132,"median":-3.856458,"eighty":-2.546837,"marketCap":101332133},{"date":"2025-08-22","current":-2.596205,"twenty":-6.1132,"median":-3.856458,"eighty":-2.541658,"marketCap":110008891},{"date":"2025-08-29","current":-2.545012,"twenty":-6.033244,"median":-3.838191,"eighty":-2.530385,"marketCap":107839701},{"date":"2025-09-05","current":-2.74247,"twenty":-6.003302,"median":-3.805323,"eighty":-2.498872,"marketCap":116206575},{"date":"2025-09-12","current":-3.115445,"twenty":-5.964031,"median":-3.793648,"eighty":-2.525066,"marketCap":132010669},{"date":"2025-09-19","current":-2.881421,"twenty":-5.898952,"median":-3.776855,"eighty":-2.539403,"marketCap":122094374},{"date":"2025-09-26","current":-2.632771,"twenty":-5.861816,"median":-3.757875,"eighty":-2.544341,"marketCap":111558312},{"date":"2025-10-03","current":-3.28365,"twenty":-5.684705,"median":-3.738896,"eighty":-2.546472,"marketCap":139138005},{"date":"2025-10-10","current":-1.257879,"twenty":-5.595667,"median":-3.729992,"eighty":-2.525066,"marketCap":53300082},{"date":"2025-10-17","current":-1.060422,"twenty":-5.58412,"median":-3.727909,"eighty":-2.468814,"marketCap":44933209},{"date":"2025-10-24","current":-1.060422,"twenty":-5.516043,"median":-3.699343,"eighty":-2.388509,"marketCap":44933209},{"date":"2025-10-31","current":-1.075048,"twenty":-5.447334,"median":-3.691448,"eighty":-2.317303,"marketCap":45552977},{"date":"2025-11-07","current":-1.111614,"twenty":-5.371836,"median":-3.676368,"eighty":-2.244599,"marketCap":47102398},{"date":"2025-11-14","current":-0.828708,"twenty":-5.321912,"median":-3.651662,"eighty":-2.178806,"marketCap":42454135},{"date":"2025-11-21","current":-0.782205,"twenty":-5.233356,"median":-3.64221,"eighty":-2.124921,"marketCap":40071826},{"date":"2025-11-28","current":-0.819751,"twenty":-5.18765,"median":-3.621859,"eighty":-2.093402,"marketCap":41995273},{"date":"2025-12-05","current":-0.757174,"twenty":-5.110521,"median":-3.608617,"eighty":-2.055444,"marketCap":38789527},{"date":"2025-12-12","current":-0.719628,"twenty":-5.037066,"median":-3.577936,"eighty":-2.025264,"marketCap":36866080},{"date":"2025-12-19","current":-0.625701,"twenty":-4.9588,"median":-3.549105,"eighty":-1.981949,"marketCap":32054255},{"date":"2025-12-26","current":-0.522137,"twenty":-4.912548,"median":-3.544049,"eighty":-1.945365,"marketCap":26748745},{"date":"2026-01-02","current":-0.469135,"twenty":-4.89913,"median":-3.530125,"eighty":-1.880836,"marketCap":24033478},{"date":"2026-01-09","current":-0.657052,"twenty":-4.893905,"median":-3.501657,"eighty":-1.841207,"marketCap":33660334},{"date":"2026-01-16","current":-0.60236,"twenty":-4.863947,"median":-3.501004,"eighty":-1.780246,"marketCap":30858511},{"date":"2026-01-23","current":-0.657052,"twenty":-4.827714,"median":-3.463671,"eighty":-1.698098,"marketCap":33660334},{"date":"2026-01-30","current":-0.600733,"twenty":-4.820607,"median":-3.430485,"eighty":-1.632257,"marketCap":30775162},{"date":"2026-02-06","current":-0.500298,"twenty":-4.784865,"median":-3.387782,"eighty":-1.562303,"marketCap":25629940},{"date":"2026-02-13","current":-0.451176,"twenty":-4.684882,"median":-3.355987,"eighty":-1.389518,"marketCap":23113429},{"date":"2026-02-20","current":-0.488221,"twenty":-4.650603,"median":-3.310888,"eighty":-1.249103,"marketCap":25011231},{"date":"2026-02-27","current":-0.482464,"twenty":-4.611231,"median":-3.270848,"eighty":-1.139404,"marketCap":24716302},{"date":"2026-03-06","current":-0.461814,"twenty":-4.588626,"median":-3.232166,"eighty":-1.117465,"marketCap":23658406},{"date":"2026-03-13","current":-0.421973,"twenty":-4.584426,"median":-3.115445,"eighty":-1.099913,"marketCap":23598786},{"date":"2026-03-19","current":-0.4018,"twenty":-4.568894,"median":-3.077727,"eighty":-1.060422,"marketCap":22470583}],"updateTime":1774063133421},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SKYE\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620627173","title":"Skye Bioscience receives Nasdaq notice for SKYE bid price below $1 for 30 days","url":"https://stock-news.laohu8.com/highlight/detail?id=2620627173","media":"Reuters","labels":["shareholding","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620627173?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:20","pubTimestamp":1773955220,"startTime":"0","endTime":"0","summary":"Skye received a Nasdaq notice stating its common stock bid price had closed below $1 for 30 consecutive business days, breaching Nasdaq Listing Rule 5450.The company has until September 14, 2026 to regain compliance, and it can do so if the bid price closes at $1 or more for at least 10 consecutive business days.A reverse stock split is one option, but it would need to be completed no later than 10 business days before September 14, 2026.If compliance is not regained by that deadline, Skye may be eligible for an additional 180-day period if it meets other Nasdaq Capital Market listing standards.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via EDGAR,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL2Vp0Vx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2618928481","title":"Skye Bioscience (SKYE) Receives a Hold from Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2618928481","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618928481?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:27","pubTimestamp":1773235640,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Kristen Kluska maintained a Hold rating on Skye Bioscience yesterday and set a price target of $2.00. The company’s share...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/skye-bioscience-skye-receives-a-hold-from-cantor-fitzgerald-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/skye-bioscience-skye-receives-a-hold-from-cantor-fitzgerald-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2618912400","title":"Analysts Offer Insights on Healthcare Companies: Skye Bioscience (SKYE) and Sandoz Group Ltd (OtherSDZXF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2618912400","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618912400?lang=en_us&edition=fundamental","pubTime":"2026-03-11 16:30","pubTimestamp":1773217807,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Skye Bioscience (SKYE – Research Report) and Sando...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-skye-bioscience-skye-and-sandoz-group-ltd-othersdzxf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-skye-bioscience-skye-and-sandoz-group-ltd-othersdzxf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","HCSG","LU0029874061.USD","BK4139","BK4585","BK4588","BK4137","LU0128526141.USD","LABU","SKYE","XBI","XLV"],"gpt_icon":0},{"id":"2618696141","title":"Skye Bioscience Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2618696141","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618696141?lang=en_us&edition=fundamental","pubTime":"2026-03-11 05:01","pubTimestamp":1773176475,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc reports results for the quarter ended December 31 - Earnings SummarySkye Bioscience Inc SKYE.OQ reported a quarterly adjusted loss of 36 cents per share for the quarter ended Decem","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL8N3ZY2N0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2618966184","title":"Skye Bioscience Q4 EPS $(0.36) Misses $(0.30) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2618966184","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618966184?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:02","pubTimestamp":1773172933,"startTime":"0","endTime":"0","summary":"Skye Bioscience (NASDAQ:SKYE) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.30) by 21.21 percent. This is a 50 percent decrease over losses of $(0.24) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51172692/skye-bioscience-q4-eps-0-36-misses-0-30-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Skye Bioscience Q4 EPS $(0.36) Misses $(0.30) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2618669539","title":"Skye Bioscience FY 2025 net loss rises 111% to USD 55.92 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2618669539","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618669539?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:01","pubTimestamp":1773172913,"startTime":"0","endTime":"0","summary":"Skye Bioscience reported a Q4 net loss of USD 14.44 million, widening 48%, and R&D expenses of USD 11.47 million, up 47% mainly due to contracted manufacturing costs tied to anticipated Phase 2b supply and employee-related benefits. For FY 2025, net loss widened to USD 55.92 million and R&D expenses more than doubled to USD 42.36 million, driven primarily by contracted clinical study and manufacturing costs for nimacimab and increased discovery research and compensation. Cash, cash equivalents and short-term investments were USD 25.7 million at year-end, and Skye said this is expected to fund operations and key clinical milestones through Q4 2026, excluding the anticipated clinical cost of a proposed Phase 2b trial and additional manufacturing to supply such a study. Skye said it initiated the CBeyond Expansion Study  with 400 mg and 600 mg IV weekly nimacimab monotherapy cohorts versus placebo over 15 weeks, and expects topline data in Q4 2026. CEO Punit Dhillon said CBeyond showed a ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL6CnrV0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4112","LU2095319765.USD","LU2210149790.SGD","LU2210150020.SGD","IE00BKPKM429.USD","LU0314104364.USD","SKYE","SG9999014005.SGD","BK4585","SG9999014013.SGD","BK4588","SG9999014021.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","NDAQ","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2618966955","title":"Press Release: Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2618966955","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618966955?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:01","pubTimestamp":1773172860,"startTime":"0","endTime":"0","summary":"-- Initiated higher-dose CBeyond Expansion Study  to generate. higher-exposure human safety and pharmacokinetic data with 400 mg and 600. -- Received written FDA Type C meeting minutes; feedback is informing key. Phase 2b combination design elements and the Company's ongoing evaluation. of a potential add-on development path with incretin therapy;-- Presented new body composition data demonstrating differentiated weight. maintenance profile for patients that have discontinued combination. conjugate platform, a single unimolecular therapeutic of nimacimab-GLP1RA. SAN DIEGO, March 10, 2026  -- Skye Bioscience, Inc.  , a clinical stage biopharmaceutical company pioneering next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025, along with key accomplishments and upcoming milestones.-- Initiated the Expansion Study of CBeyond to ass","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1066053197.SGD","BK4232","LU1066051498.USD","LU1935042488.USD","LU1066051811.HKD","LU0157215616.USD","SKYE","LU1674673428.USD","LU1366333091.USD","LU2237443382.USD","LU1935042215.USD","LU0786609619.USD","LU1066051225.USD","LU0077335932.USD","LU1366192091.USD","LU2456880835.USD","LU0170899867.USD","LU0882574139.USD","LU1935043536.SGD","LU2420271590.USD","LU0053666078.USD","LU1935042991.SGD","LU1778281490.HKD","BK4022","LU1674673691.USD","LU0149725797.USD","LU2236285917.USD","LU0314104364.USD","LU1718418525.SGD","LU1935043023.USD","BK4214","APC","R","LU2083900584.USD","LU2237443622.USD","LU2237443978.SGD","LU1496350171.SGD","BK4139","LU2417539215.USD","LU2237443549.SGD"],"gpt_icon":0},{"id":"2617020637","title":"Skye Bioscience Inc  expected to post a loss of 30 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2617020637","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617020637?lang=en_us&edition=fundamental","pubTime":"2026-03-07 04:05","pubTimestamp":1772827506,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc  expected to post a loss of30cents a share - Earnings Preview Skye Bioscience Inc SKYE.OQ SKYE.O is expected to  show no change in quarterly revenue when it reports  results on Mar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL8N3ZU2GJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2617754170","title":"Skye Bioscience Publishes Corporate Presentation on Nimacimab-Semaglutide Obesity Combination Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2617754170","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617754170?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:09","pubTimestamp":1772712583,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. released a corporate presentation outlining its obesity and metabolic disease pipeline, highlighting nimacimab, a peripherally restricted CB1-inhibiting antibody being evaluated in combination with semaglutide. The presentation summarizes Phase 2a CBeyond data showing 13 percent weight loss at 26 weeks for the combination versus semaglutide alone, and interim extension data indicating 22.3 percent total weight loss at 52 weeks with no plateau observed. It also reports reduced post-treatment weight regain in off-therapy follow-up for the combination versus semaglutide alone, along with a tolerability profile that did not show additive gastrointestinal burden or neuropsychiatric adverse events in the combination arm. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDLbTZ46y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2617549541","title":"Skye Bioscience Inc. to Announce 2025 Financial Results and Business Update on Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2617549541","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617549541?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:00","pubTimestamp":1772712057,"startTime":"0","endTime":"0","summary":"Skye Bioscience will announce its 2025 fourth quarter and full-year financial results on March 10, 2026, with an earnings press release issued after the market closes and made available on the Investor Relations website. Skye Bioscience will host a conference call on March 10, 2026 at 1:30 p.m. PT / 4:30 p.m. ET to discuss its 2025 fourth quarter and full-year financial results and provide a business update; the live webcast can be accessed via the Investor Relations website.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nNDLbN0VMp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BKPKM429.USD","LU2210149790.SGD","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","SG9999014005.SGD","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","SG9999014013.SGD","BK4139","SKYE","IE00B3QW5Z07.USD","BK4585","SG9999014021.USD","LU2210150020.SGD","SG9999014039.USD"],"gpt_icon":0},{"id":"2613422381","title":"Skye Bioscience Publishes Corporate Presentation on Nimacimab–Semaglutide Obesity Combination Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2613422381","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613422381?lang=en_us&edition=fundamental","pubTime":"2026-02-22 09:32","pubTimestamp":1771723950,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. released a corporate presentation highlighting its obesity and metabolic disease program centered on nimacimab, a peripherally restricted CB1-inhibiting antibody, including development plans for use in combination with semaglutide. The presentation summarizes Phase 2a CBeyond data showing 13% weight loss at 26 weeks for nimacimab plus semaglutide versus semaglutide alone , and interim extension data indicating 22.3% total weight loss at 52 weeks in the combination group with no plateau observed. It also reports reduced post-treatment weight rebound over a 13-week off-therapy follow-up  and notes tolerability observations in the combination arm, including no additive gastrointestinal burden and no neuropsychiatric adverse events reported. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260222:nNDL1nTf1B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2613621893","title":"BRIEF-Skye Bioscience Says Kaitlyn Arsenault To Step Down As CFO Effective Feb 20","url":"https://stock-news.laohu8.com/highlight/detail?id=2613621893","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613621893?lang=en_us&edition=fundamental","pubTime":"2026-02-21 06:35","pubTimestamp":1771626923,"startTime":"0","endTime":"0","summary":"BRIEF-Skye Bioscience Says Kaitlyn Arsenault To Step Down As CFO Effective Feb 20Feb 20  - Skye Bioscience Inc SKYE.O:SKYE BIOSCIENCE INC - KAITLYN ARSENAULT TO STEP DOWN AS CFO EFFECTIVE FEB 20, 2026 - SEC FILINGSource text: [ID:n0001628280-26-010186]Further company coverage: SKYE.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nFWN3ZG0SV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2613297369","title":"Skye Bioscience Inc - Kaitlyn Arsenault to Step Down as CFO Effective Feb 20, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2613297369","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613297369?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:08","pubTimestamp":1771621728,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nFWN3ZG0SV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2613973372","title":"Skye Bioscience CFO Kaitlyn Arsenault to Step Down as CEO Punit Dhillon Becomes Principal Accounting Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2613973372","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613973372?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:06","pubTimestamp":1771621567,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. said Chief Financial Officer Kaitlyn Arsenault will step down effective February 20, 2026, to pursue new opportunities. The company will retain Arsenault as an advisor for transition-related services. Skye Bioscience President and CEO Punit Dhillon was appointed principal accounting officer effective February 20, 2026, while continuing in his current roles.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Skye Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL5xtsvd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2612116460","title":"Halozyme 2025 revenue up 38%, Q4 EPS misses estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2612116460","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612116460?lang=en_us&edition=fundamental","pubTime":"2026-02-18 05:09","pubTimestamp":1771362566,"startTime":"0","endTime":"0","summary":"Halozyme 2025 revenue up 38%, Q4 EPS misses estimatesOverviewBiopharmaceutical firm's 2025 revenue rose 38% to $1.4 bln, driven by ENHANZE growthQ4 adjusted EPS missed analyst expectationsCompany comp","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nL1N3ZD0XQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","BK4139","SKYE","HALO"],"gpt_icon":0},{"id":"2608765866","title":"BRIEF-Skye Reports Positive Cbeyond Phase 2A Extension Interim Study Results For Nimacimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2608765866","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608765866?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:26","pubTimestamp":1770035179,"startTime":"0","endTime":"0","summary":"BRIEF-Skye Reports Positive Cbeyond Phase 2A Extension Interim Study Results For NimacimabFeb 2 (Reuters) - Skye Bioscience Inc SKYE.O:SKYE REPORTS POSITIVE CBEYOND PHASE 2A EXTENSION INTERIM STUDY RE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA1KWJJS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2608586571","title":"Skye Bioscience Reports 22% Weight Loss at 52 Weeks With Nimacimab and Semaglutide Combination in Phase 2a Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2608586571","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608586571?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:01","pubTimestamp":1770033708,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc. announced interim 52-week data from the extension phase of its Phase 2a CBeyond proof-of-concept study evaluating nimacimab, a peripherally-restricted CB1 inhibitor antibody, in combination with semaglutide for obesity and metabolic disorders. The results showed a 22.3% total weight loss at 52 weeks for the combination of nimacimab  and semaglutide , with no plateau observed, suggesting the potential for continued efficacy beyond one year and at higher nimacimab doses. The combination also demonstrated a reduction in weight regain during a 13-week treatment interruption, with participants regaining 17.8% of weight lost compared to 37.3% for semaglutide alone. The safety and tolerability profile remained strong, with no serious adverse events reported. Full topline data, including nimacimab monotherapy results and off-therapy follow-up, are expected to be reported in Q3 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDL6qrSg5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014039.USD","NDAQ","SKYE","LU2210149790.SGD","LU2210150020.SGD","SG9999014013.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","BK4585","SG9999014005.SGD","BK4139","IE00B64PRP62.GBP","BK4112","BK4588"],"gpt_icon":0},{"id":"2608786528","title":"Skye Bioscience Inc - 22.3% Weight Loss at 52 Weeks With Nimacimab + Semaglutide (2.4 Mg) Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2608786528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608786528?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:00","pubTimestamp":1770033602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA1KWJJS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SKYE"],"gpt_icon":0},{"id":"2608586528","title":"Skye Bioscience Inc - Full Topline Reporting of Cbeyond Phase 2a Data Expected Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2608586528","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608586528?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:00","pubTimestamp":1770033602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA1KWJJS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SKYE","BK4139"],"gpt_icon":0},{"id":"2608243865","title":"Skye Reports Positive Cbeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide","url":"https://stock-news.laohu8.com/highlight/detail?id=2608243865","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608243865?lang=en_us&edition=fundamental","pubTime":"2026-02-02 20:00","pubTimestamp":1770033602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUA1KWJJS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SKYE"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":67,"code":"91000000","status":"200"}]}}